SEC 13F Intelligence

Managers / Q4 2023 · view latest →

72 Investment Holdings, LLC

CIK 0001832749 · 72 CUMMINGS POINT ROAD, STAMFORD, CT, 06902 · 203-890-2000

Reported Value
$23M
Q4 2023
Positions
6
Filings on Record
22
2021–present window
Filed
Feb 14, 2024
original filing

Summary

72 Investment Holdings, LLC reported $23M in U.S.-listed holdings across 6 positions for Q4 2023.

The portfolio is heavily concentrated: KRRO alone accounts for 58.9% of reported value.

Compared with Q3 2023, the fund opened 2 new positions and exited 1.

Portfolio Metrics

Turnover
+42.2%
vs prior filed quarter
Largest Position
+58.9%
Korro Bio
New / Exited
2 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $742MQ4 ’20Q1 ’21: $66MQ2 ’21: $63MQ3 ’21: $80MQ3 ’21Q4 ’21: $113MQ1 ’22: $91MQ2 ’22: $65MQ2 ’22Q3 ’22: $126MQ4 ’22: $218MQ1 ’23: $211MQ1 ’23Q2 ’23: $13MQ3 ’23: $15MQ4 ’23: $23MQ4 ’23Q1 ’24: $67MQ2 ’24: $40MQ3 ’24: $47MQ3 ’24Q4 ’24: $49MQ1 ’25: $36MQ2 ’25: $38MQ2 ’25Q3 ’25: $68MQ4 ’25: $51MQ1 ’26: $50MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 89.1%Other: 10.9%
  • Common Stock · 89.1% · $20M
  • Other · 10.9% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
KRROKORRO BIO INCNEW+276.8K276.8K+$13M$13M
PRAXPRAXIS PRECISION MEDICINES INEW+65.9K65.9K+$1M$1M
PRAXIS PRECISION MEDICINES ISOLD OUT−989.0K0−$2M$0
TRDAENTRADA THERAPEUTICS INCTRIMMED−336.4K172.6K−$5M$3M
TURNSTONE BIOLOGICS CORPHELD+0550.0K−$767,223$1M
CRBUCARIBOU BIOSCIENCES INCHELD+0474.1K+$450,364$3M
OMEGA THERAPEUTICS INCHELD+0352.9K+$303,529$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2023

6 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1KRROKORRO BIO INChistory →COM58.92%$13M276.8K
2CRBUCARIBOU BIOSCIENCES INChistory →COM12.06%$3M474.1K
3TRDAENTRADA THERAPEUTICS INChistory →COM11.57%$3M172.6K
4PRAXPRAXIS PRECISION MEDICINES Ihistory →COM NEW6.52%$1M65.9K
5TURNSTONE BIOLOGICS CORPCOM6.22%$1M550.0K
6OMEGA THERAPEUTICS INCCOMMON STOCK4.72%$1M352.9K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$50M5May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$51M5Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$68M5Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$38M6Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$36M6May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$49M7Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$47M7Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$40M7Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$67M7May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$23M6Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$15M5Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$13M4Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$211M5May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$218M5Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$126M5Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$65M5Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$91M6May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$113M6Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$80M4Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$63M2Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$66M2May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$742M2Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.